Roche’s Enspryng demonstrates potential to become first treatment for MOGAD

Swiss pharma giant Roche (ROG: SIX) has announced new data from the Phase III METEOROID study demonstrating that Enspryng (satralizumab) reduced the risk of a new relapse by 68% compared to placebo in adults and adolescents with myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), meeting its primary endpoint.

The primary endpoint was measured by the time from randomization to the first MOGAD relapse during the double-blind treatment period (p=0.0025). The results were shared today at a late-breaking oral presentation in the Clinical Trials Plenary Session at the 2026 American Academy of Neurology (AAN) Annual Meeting in Chicago.